Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6611267 | 1.00 | APP (0.60) | APP | |
| SCHEMBL6610438 | 0.97 | APP (0.57) | APP | |
| SCHEMBL6682082 | 0.97 | APP (0.57) | APP | |
| SCHEMBL6614208 | 0.95 | APP (0.60) | APP | |
| SCHEMBL6802804 | 0.95 | APP (0.60) | APP | |
| SCHEMBL6614254 | 0.89 | MAOB (0.63) | — | |
| SCHEMBL6808356 | 0.89 | MAOB (0.63) | — | |
| SCHEMBL6612003 | 0.82 | MAOB (0.68) | APP | |
| SCHEMBL6609593 | 0.82 | APP (0.58) | APP | |
| SCHEMBL6809150 | 0.82 | APP (0.58) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | claimed |
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132807-A1 | Aurones as telomerase inhibitors | TERT, TERF2, TERF2IP | APP 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.